Sander F Garrelfs1, Yaacov Frishberg1, Sally A Hulton1, Michael J Koren1, William D O'Riordan1, Pierre Cochat1, Georges Deschênes1, Hadas Shasha-Lavsky1, Jeffrey M Saland1, William G Van't Hoff1, Daniel G Fuster1, Daniella Magen1, Shabbir H Moochhala1, Gesa Schalk1, Eva Simkova1, Jaap W Groothoff1, David J Sas1, Kristin A Meliambro1, Jiandong Lu1, Marianne T Sweetser1, Pushkal P Garg1, Akshay K Vaishnaw1, John M Gansner1, Tracy L McGregor1, John C Lieske1. 1. From the Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam (S.F.G., J.W.G.); the Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem (Y.F.); the Department of Nephrology, Birmingham Women's and Children's Hospital, Birmingham (S.A.H.), and the Department of Paediatric Nephrology, Great Ormond Street Hospital (W.G.H.), and UCL Department of Renal Medicine, Royal Free Hospital (S.H.M.), London - both in the United Kingdom; Jacksonville Center for Clinical Research, Jacksonville, FL (M.J.K.); eStudySite, San Diego, CA (W.D.O.); Center for Rare Renal Diseases and INSERM Pediatric Clinical Investigation Center-Hospices Civils de Lyon and Université de Lyon, Lyon (P.C.), and the Department of Pediatric Nephrology, Hôpital Robert-Debré, Paris (G.D.) - both in France; the Pediatric Nephrology Unit, Galilee Medical Center, Nahariya (H.S.-L.), and the Pediatric Nephrology Institute, Rambam Health Care Campus, Haifa (D.M.) - both in Israel; the Icahn School of Medicine at Mount Sinai, New York (J.M.S., K.A.M.); the Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland (D.G.F.); the University of Bonn, Bonn, Germany (G.S.); Al Jalila Children's Hospital, Dubai, United Arab Emirates (E.S.); the Divisions of Pediatric Nephrology and Hypertension (D.J.S.) and Nephrology and Hypertension (J.C.L.), Mayo Clinic, Rochester, MN; and Alnylam Pharmaceuticals, Cambridge, MA (J.L., M.T.S., P.P.G., A.K.V., J.M.G., T.L.M.).
Abstract
BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. METHODS: In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with PH1 who were 6 years of age or older to receive subcutaneous lumasiran or placebo for 6 months (with doses given at baseline and at months 1, 2, 3, and 6). The primary end point was the percent change in 24-hour urinary oxalate excretion from baseline to month 6 (mean percent change across months 3 through 6). Secondary end points included the percent change in the plasma oxalate level from baseline to month 6 (mean percent change across months 3 through 6) and the percentage of patients with 24-hour urinary oxalate excretion no higher than 1.5 times the upper limit of the normal range at month 6. RESULTS: A total of 39 patients underwent randomization; 26 were assigned to the lumasiran group and 13 to the placebo group. The least-squares mean difference in the change in 24-hour urinary oxalate excretion (lumasiran minus placebo) was -53.5 percentage points (P<0.001), with a reduction in the lumasiran group of 65.4% and an effect seen as early as month 1. The between-group differences for all hierarchically tested secondary end points were significant. The difference in the percent change in the plasma oxalate level (lumasiran minus placebo) was -39.5 percentage points (P<0.001). In the lumasiran group, 84% of patients had 24-hour urinary oxalate excretion no higher than 1.5 times the upper limit of the normal range at month 6, as compared with 0% in the placebo group (P<0.001). Mild, transient injection-site reactions were reported in 38% of lumasiran-treated patients. CONCLUSIONS: Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. The majority of patients who received lumasiran had normal or near-normal levels after 6 months of treatment. (Funded by Alnylam Pharmaceuticals; ILLUMINATE-A ClinicalTrials.gov number, NCT03681184.).
BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. METHODS: In this double-blind, phase 3 trial, we randomly assigned (in a 2:1 ratio) patients with PH1 who were 6 years of age or older to receive subcutaneous lumasiran or placebo for 6 months (with doses given at baseline and at months 1, 2, 3, and 6). The primary end point was the percent change in 24-hour urinary oxalate excretion from baseline to month 6 (mean percent change across months 3 through 6). Secondary end points included the percent change in the plasma oxalate level from baseline to month 6 (mean percent change across months 3 through 6) and the percentage of patients with 24-hour urinary oxalate excretion no higher than 1.5 times the upper limit of the normal range at month 6. RESULTS: A total of 39 patients underwent randomization; 26 were assigned to the lumasiran group and 13 to the placebo group. The least-squares mean difference in the change in 24-hour urinary oxalate excretion (lumasiran minus placebo) was -53.5 percentage points (P<0.001), with a reduction in the lumasiran group of 65.4% and an effect seen as early as month 1. The between-group differences for all hierarchically tested secondary end points were significant. The difference in the percent change in the plasma oxalate level (lumasiran minus placebo) was -39.5 percentage points (P<0.001). In the lumasiran group, 84% of patients had 24-hour urinary oxalate excretion no higher than 1.5 times the upper limit of the normal range at month 6, as compared with 0% in the placebo group (P<0.001). Mild, transient injection-site reactions were reported in 38% of lumasiran-treated patients. CONCLUSIONS: Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. The majority of patients who received lumasiran had normal or near-normal levels after 6 months of treatment. (Funded by Alnylam Pharmaceuticals; ILLUMINATE-A ClinicalTrials.gov number, NCT03681184.).
Authors: Sander Garrelfs; Dewi van Harskamp; Hessel Peters-Sengers; Chris van den Akker; Ronald Wanders; Frits Wijburg; Johannes van Goudoever; Jaap Groothoff; Henk Schierbeek; Michiel Oosterveld Journal: J Am Soc Nephrol Date: 2021-10-22 Impact factor: 10.121
Authors: Shu Ning; Chengfei Liu; Wei Lou; Joy C Yang; Alan P Lombard; Leandro S D'Abronzo; Neelu Batra; Ai-Ming Yu; Amy R Leslie; Masuda Sharifi; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2022-10-07 Impact factor: 6.009
Authors: Naeem Bhojani; Jennifer Bjazevic; Brendan Wallace; Linda Lee; Kamaljot S Kaler; Marie Dion; Andrea Cowan; Nabil Sultan; Ben H Chew; Hassan Razvi Journal: Can Urol Assoc J Date: 2022-06 Impact factor: 2.052
Authors: Kirk M Brown; Jayaprakash K Nair; Maja M Janas; Yesseinia I Anglero-Rodriguez; Lan T H Dang; Haiyan Peng; Christopher S Theile; Elena Castellanos-Rizaldos; Christopher Brown; Donald Foster; Jeffrey Kurz; Jeffrey Allen; Rajanikanth Maganti; Jing Li; Shigeo Matsuda; Matthew Stricos; Tyler Chickering; Michelle Jung; Kelly Wassarman; Jeff Rollins; Lauren Woods; Alex Kelin; Dale C Guenther; Melissa W Mobley; John Petrulis; Robin McDougall; Timothy Racie; Jessica Bombardier; Diana Cha; Saket Agarwal; Lei Johnson; Yongfeng Jiang; Scott Lentini; Jason Gilbert; Tuyen Nguyen; Samantha Chigas; Sarah LeBlanc; Urjana Poreci; Anne Kasper; Arlin B Rogers; Saeho Chong; Wendell Davis; Jessica E Sutherland; Adam Castoreno; Stuart Milstein; Mark K Schlegel; Ivan Zlatev; Klaus Charisse; Mark Keating; Muthiah Manoharan; Kevin Fitzgerald; Jing-Tao Wu; Martin A Maier; Vasant Jadhav Journal: Nat Biotechnol Date: 2022-06-02 Impact factor: 68.164
Authors: Hillarey K Stone; Katherine VandenHeuvel; Alexander Bondoc; Francisco X Flores; David K Hooper; Charles D Varnell Journal: Am J Transplant Date: 2021-07-29 Impact factor: 8.086
Authors: Prince Singh; Candace F Granberg; Peter C Harris; John C Lieske; Jeffrey H Licht; Andrew Weiss; Dawn S Milliner Journal: Am J Kidney Dis Date: 2021-07-07 Impact factor: 11.072